Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
100 participants
INTERVENTIONAL
2023-08-01
2025-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects
NCT02696291
Zinc and Green Tea Extract for Community Respiratory Viral Infections
NCT04898023
A Study to Evaluate the Safety, Tolerability and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections
NCT05030324
A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine
NCT05067933
Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy Volunteers
NCT03459391
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention
Participants consume twice per day a study drink which contains 0,75 mg soluble Xanthohumol for 90 days
Xanthohumol
Participants consume twice per day a study drink which contains 0,75 mg soluble Xanthohumol for 90 days
Placebo
Participants consume twice per day a study drink which contains 0 mg soluble Xanthohumol for 90 days
Placebo
Participants consume twice per day a study drink which contains 0 mg soluble Xanthohumol for 90 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Xanthohumol
Participants consume twice per day a study drink which contains 0,75 mg soluble Xanthohumol for 90 days
Placebo
Participants consume twice per day a study drink which contains 0 mg soluble Xanthohumol for 90 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI \>18 kg/m² or \< 28kg/m²
Exclusion Criteria
* food allergies
* chronic inflammatory diseases
* metabolic diseases
* viral or bacterial infections within the last 3 weeks of inclusion
* intake of immunosuppressive medication
* severe acute respiratory syndrome coronavirus type 2-infection in the last 4 months
* influenza infection in the "current" flu season
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Vienna
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Dr. Ina Bergheim
Prof. Dr. Ina Bergheim
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Vienna
Vienna, , Austria
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UVienna23a
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.